Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23027448 | 0.83 | — | — | |
| SCHEMBL30887221 | 0.83 | — | — | |
| SCHEMBL22631526 | 0.82 | SLC6A4 (0.32) | ALDH1A1 | |
| SCHEMBL13842050 | 0.81 | PPARA (0.31) | PPARA | |
| SCHEMBL8876640 | 0.80 | PPARA (0.33) | PPARA | |
| SCHEMBL710380 | 0.77 | BRD4 (0.31) | — | |
| SCHEMBL13130047 | 0.77 | APP (0.33) | PPARA | |
| SCHEMBL31668617 | 0.76 | — | — | |
| SCHEMBL19619093 | 0.71 | TSHR (0.46) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL19080527 | 0.71 | CYP1A2 (0.43) | MEN1KMT2AHTTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242036-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | APOSENSE LTD. (IL) | 2025-07-31 | — | — | US | disclosed |
| EP-4590338-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | Aposense Ltd. (IL) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024062489-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | APOSENSE LTD. (IL) | 2024-03-28 | — | — | WO | disclosed |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242036-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | HAVCR2, SLC47A2, SLC47A1 | TSHR 1773/4885MEN1 1397/4885KMT2A 4194/4885 |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | LDLR, NPC1L1, ABCB4 | TSHR 2243/4885MEN1 1858/4885KMT2A 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.